Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

LAES vs XTLB vs CODA vs IDAI vs INVE

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
LAES
SEALSQ Corp

Semiconductors

TechnologyNASDAQ • CH
Market Cap$108M
5Y Perf.-74.6%
XTLB
XTL Biopharmaceuticals Ltd.

Biotechnology

HealthcareNASDAQ • IL
Market Cap$294K
5Y Perf.-45.7%
CODA
Coda Octopus Group, Inc.

Aerospace & Defense

IndustrialsNASDAQ • US
Market Cap$134M
5Y Perf.+12.4%
IDAI
T Stamp Inc.

Software - Application

TechnologyNASDAQ • US
Market Cap$3M
5Y Perf.-93.5%
INVE
Identiv, Inc.

Computer Hardware

TechnologyNASDAQ • US
Market Cap$120M
5Y Perf.-30.7%

LAES vs XTLB vs CODA vs IDAI vs INVE — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
LAES logoLAES
XTLB logoXTLB
CODA logoCODA
IDAI logoIDAI
INVE logoINVE
IndustrySemiconductorsBiotechnologyAerospace & DefenseSoftware - ApplicationComputer Hardware
Market Cap$108M$294K$134M$3M$120M
Revenue (TTM)$35M$451K$28M$4M$22M
Net Income (TTM)$-50M$-1M$4M$-12M$-15M
Gross Margin37.3%26.4%66.3%60.0%-3.6%
Operating Margin-136.9%-481.6%17.4%-183.3%-109.3%
Forward P/E22.5x1.6x
Total Debt$9M$138K$395K$4M$2M
Cash & Equiv.$85M$371K$29M$3M$136M

LAES vs XTLB vs CODA vs IDAI vs INVELong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

LAES
XTLB
CODA
IDAI
INVE
StockMay 23May 26Return
SEALSQ Corp (LAES)10025.4-74.6%
XTL Biopharmaceutic… (XTLB)10054.3-45.7%
Coda Octopus Group,… (CODA)100112.4+12.4%
T Stamp Inc. (IDAI)1006.5-93.5%
Identiv, Inc. (INVE)10069.3-30.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: LAES vs XTLB vs CODA vs IDAI vs INVE

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CODA leads in 4 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and profitability and margin quality. Identiv, Inc. is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
LAES
SEALSQ Corp
The Technology Pick

LAES plays a supporting role in this comparison — it may shine differently against other peers.

Best for: technology exposure
XTLB
XTL Biopharmaceuticals Ltd.
The Healthcare Pick

XTLB lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
CODA
Coda Octopus Group, Inc.
The Income Pick

CODA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 0 yrs, beta 1.00
  • Rev growth 30.7%, EPS growth 15.6%, 3Y rev CAGR 6.1%
  • 8.4% 10Y total return vs INVE's 78.7%
  • 30.7% revenue growth vs XTLB's -173.2%
Best for: income & stability and growth exposure
IDAI
T Stamp Inc.
The Technology Pick

Among these 5 stocks, IDAI doesn't own a clear edge in any measured category.

Best for: technology exposure
INVE
Identiv, Inc.
The Defensive Pick

INVE is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.

  • Lower volatility, beta 0.87, Low D/E 1.3%, current ratio 19.20x
  • Beta 0.87, current ratio 19.20x
  • Better valuation composite
  • Beta 0.87 vs LAES's 3.10, lower leverage
Best for: sleep-well-at-night and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthCODA logoCODA30.7% revenue growth vs XTLB's -173.2%
ValueINVE logoINVEBetter valuation composite
Quality / MarginsCODA logoCODA14.8% margin vs IDAI's -316.4%
Stability / SafetyINVE logoINVEBeta 0.87 vs LAES's 3.10, lower leverage
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)CODA logoCODA+78.9% vs XTLB's -50.9%
Efficiency (ROA)CODA logoCODA6.6% ROA vs IDAI's -105.4%, ROIC 11.2% vs -219.6%

LAES vs XTLB vs CODA vs IDAI vs INVE — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

LAESSEALSQ Corp
FY 2024
Semiconductors
48.0%$7M
Total
48.0%$7M
Corporate
4.0%$611,000
XTLBXTL Biopharmaceuticals Ltd.

Segment breakdown not available.

CODACoda Octopus Group, Inc.
FY 2025
Equipment Sales
71.3%$14M
Service
17.3%$4M
Equipment Rentals
7.3%$1M
Software Sales
4.0%$811,912
IDAIT Stamp Inc.
FY 2024
Professional Services (Over Time)
72.5%$2M
License Fees (Over Time)
27.5%$573,000
INVEIdentiv, Inc.
FY 2023
Identity
58.5%$68M
Physical Access Control Systems
41.5%$48M

LAES vs XTLB vs CODA vs IDAI vs INVE — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLCODALAGGINGIDAI

Income & Cash Flow (Last 12 Months)

CODA leads this category, winning 4 of 6 comparable metrics.

LAES is the larger business by revenue, generating $35M annually — 78.4x XTLB's $451,000. CODA is the more profitable business, keeping 14.8% of every revenue dollar as net income compared to IDAI's -3.2%. On growth, IDAI holds the edge at +70.7% YoY revenue growth, suggesting stronger near-term business momentum.

MetricLAES logoLAESSEALSQ CorpXTLB logoXTLBXTL Biopharmaceut…CODA logoCODACoda Octopus Grou…IDAI logoIDAIT Stamp Inc.INVE logoINVEIdentiv, Inc.
RevenueTrailing 12 months$35M$451,000$28M$4M$22M
EBITDAEarnings before interest/tax-$47M-$1M$6M-$6M-$21M
Net IncomeAfter-tax profit-$50M-$1M$4M-$12M-$15M
Free Cash FlowCash after capex-$31M$0$7M-$8M-$17M
Gross MarginGross profit ÷ Revenue+37.3%+26.4%+66.3%+60.0%-3.6%
Operating MarginEBIT ÷ Revenue-136.9%-4.8%+17.4%-183.3%-109.3%
Net MarginNet income ÷ Revenue-141.3%-2.3%+14.8%-3.2%-66.5%
FCF MarginFCF ÷ Revenue-88.9%-3.7%+24.6%-2.2%-78.3%
Rev. Growth (YoY)Latest quarter vs prior year+3.1%+28.8%+70.7%-23.3%
EPS Growth (YoY)Latest quarter vs prior year+75.0%+20.0%+3.0%+32.1%-103.9%
CODA leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

XTLB leads this category, winning 2 of 3 comparable metrics.

At 1.6x trailing earnings, INVE trades at a 95% valuation discount to CODA's 32.2x P/E.

MetricLAES logoLAESSEALSQ CorpXTLB logoXTLBXTL Biopharmaceut…CODA logoCODACoda Octopus Grou…IDAI logoIDAIT Stamp Inc.INVE logoINVEIdentiv, Inc.
Market CapShares × price$108M$293,767$134M$3M$120M
Enterprise ValueMkt cap + debt − cash$32M$60,767$106M$4M-$14M
Trailing P/EPrice ÷ TTM EPS-4.49x-0.28x32.16x-0.22x1.61x
Forward P/EPrice ÷ next-FY EPS est.22.45x
PEG RatioP/E ÷ EPS growth rate7.51x
EV / EBITDAEnterprise value multiple17.85x
Price / SalesMarket cap ÷ Revenue9.79x0.65x5.05x0.89x4.49x
Price / BookPrice ÷ Book value/share1.38x0.05x2.30x0.86x0.77x
Price / FCFMarket cap ÷ FCF22.20x
XTLB leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

CODA leads this category, winning 6 of 9 comparable metrics.

CODA delivers a 7.2% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-190 for IDAI. CODA carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to IDAI's 1.30x. On the Piotroski fundamental quality scale (0–9), CODA scores 7/9 vs IDAI's 1/9, reflecting strong financial health.

MetricLAES logoLAESSEALSQ CorpXTLB logoXTLBXTL Biopharmaceut…CODA logoCODACoda Octopus Grou…IDAI logoIDAIT Stamp Inc.INVE logoINVEIdentiv, Inc.
ROE (TTM)Return on equity-42.3%-25.5%+7.2%-189.5%-9.8%
ROA (TTM)Return on assets-35.2%-17.7%+6.6%-105.4%-9.3%
ROICReturn on invested capital-165.0%-54.1%+11.2%-2.2%-50.1%
ROCEReturn on capital employed-34.0%-50.7%+8.1%-194.9%-23.6%
Piotroski ScoreFundamental quality 0–933714
Debt / EquityFinancial leverage0.11x0.03x0.01x1.30x0.01x
Net DebtTotal debt minus cash-$76M-$233,000-$28M$1M-$134M
Cash & Equiv.Liquid assets$85M$371,000$29M$3M$136M
Total DebtShort + long-term debt$9M$138,000$394,932$4M$2M
Interest CoverageEBIT ÷ Interest expense-13.04x-13.31x-22.08x
CODA leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

CODA leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in CODA five years ago would be worth $14,969 today (with dividends reinvested), compared to $95 for IDAI. Over the past 12 months, CODA leads with a +78.9% total return vs XTLB's -50.9%. The 3-year compound annual growth rate (CAGR) favors CODA at 10.4% vs IDAI's -50.0% — a key indicator of consistent wealth creation.

MetricLAES logoLAESSEALSQ CorpXTLB logoXTLBXTL Biopharmaceut…CODA logoCODACoda Octopus Grou…IDAI logoIDAIT Stamp Inc.INVE logoINVEIdentiv, Inc.
YTD ReturnYear-to-date-28.1%+11.3%+25.1%-38.4%+38.5%
1-Year ReturnPast 12 months+30.3%-50.9%+78.9%+20.9%+60.5%
3-Year ReturnCumulative with dividends-71.9%-45.7%+34.5%-87.5%-22.7%
5-Year ReturnCumulative with dividends-71.9%-80.4%+49.7%-99.1%-67.8%
10-Year ReturnCumulative with dividends-71.9%-87.3%+844.4%+102.4%+78.7%
CAGR (3Y)Annualised 3-year return-34.5%-18.4%+10.4%-50.0%-8.2%
CODA leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

INVE leads this category, winning 2 of 2 comparable metrics.

INVE is the less volatile stock with a 0.87 beta — it tends to amplify market swings less than LAES's 3.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INVE currently trades 95.1% from its 52-week high vs XTLB's 26.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricLAES logoLAESSEALSQ CorpXTLB logoXTLBXTL Biopharmaceut…CODA logoCODACoda Octopus Grou…IDAI logoIDAIT Stamp Inc.INVE logoINVEIdentiv, Inc.
Beta (5Y)Sensitivity to S&P 5003.10x1.71x1.00x1.99x0.87x
52-Week HighHighest price in past year$8.71$10.28$17.28$5.28$5.30
52-Week LowLowest price in past year$1.99$1.05$5.98$1.80$3.01
% of 52W HighCurrent price vs 52-week peak+35.0%+26.0%+68.9%+47.2%+95.1%
RSI (14)Momentum oscillator 0–10062.057.048.649.180.8
Avg Volume (50D)Average daily shares traded10.4M2.4M256K43K210K
INVE leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: LAES as "Buy", CODA as "Buy", INVE as "Buy". Consensus price targets imply 145.9% upside for LAES (target: $8) vs 9.1% for INVE (target: $6).

MetricLAES logoLAESSEALSQ CorpXTLB logoXTLBXTL Biopharmaceut…CODA logoCODACoda Octopus Grou…IDAI logoIDAIT Stamp Inc.INVE logoINVEIdentiv, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$7.50$14.00$5.50
# AnalystsCovering analysts2114
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises00
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%+2.1%+1.6%
Insufficient data to determine a leader in this category.
Key Takeaway

CODA leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). XTLB leads in 1 (Valuation Metrics).

Best OverallCoda Octopus Group, Inc. (CODA)Leads 3 of 6 categories
Loading custom metrics...

LAES vs XTLB vs CODA vs IDAI vs INVE: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is LAES or XTLB or CODA or IDAI or INVE a better buy right now?

For growth investors, Coda Octopus Group, Inc.

(CODA) is the stronger pick with 30. 7% revenue growth year-over-year, versus -63. 5% for SEALSQ Corp (LAES). Identiv, Inc. (INVE) offers the better valuation at 1. 6x trailing P/E, making it the more compelling value choice. Analysts rate SEALSQ Corp (LAES) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — LAES or XTLB or CODA or IDAI or INVE?

On trailing P/E, Identiv, Inc.

(INVE) is the cheapest at 1. 6x versus Coda Octopus Group, Inc. at 32. 2x.

03

Which is the better long-term investment — LAES or XTLB or CODA or IDAI or INVE?

Over the past 5 years, Coda Octopus Group, Inc.

(CODA) delivered a total return of +49. 7%, compared to -99. 1% for T Stamp Inc. (IDAI). Over 10 years, the gap is even starker: CODA returned +844. 4% versus XTLB's -87. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — LAES or XTLB or CODA or IDAI or INVE?

By beta (market sensitivity over 5 years), Identiv, Inc.

(INVE) is the lower-risk stock at 0. 87β versus SEALSQ Corp's 3. 10β — meaning LAES is approximately 257% more volatile than INVE relative to the S&P 500. On balance sheet safety, Coda Octopus Group, Inc. (CODA) carries a lower debt/equity ratio of 1% versus 130% for T Stamp Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — LAES or XTLB or CODA or IDAI or INVE?

By revenue growth (latest reported year), Coda Octopus Group, Inc.

(CODA) is pulling ahead at 30. 7% versus -63. 5% for SEALSQ Corp (LAES). On earnings-per-share growth, the picture is similar: Identiv, Inc. grew EPS 1183% year-over-year, compared to -223. 8% for SEALSQ Corp. Over a 3-year CAGR, CODA leads at 6. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — LAES or XTLB or CODA or IDAI or INVE?

Identiv, Inc.

(INVE) is the more profitable company, earning 281. 0% net margin versus -344. 1% for T Stamp Inc. — meaning it keeps 281. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CODA leads at 17. 1% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — CODA leads at 66. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is LAES or XTLB or CODA or IDAI or INVE more undervalued right now?

Analyst consensus price targets imply the most upside for LAES: 145.

9% to $7. 50.

08

Which pays a better dividend — LAES or XTLB or CODA or IDAI or INVE?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is LAES or XTLB or CODA or IDAI or INVE better for a retirement portfolio?

For long-horizon retirement investors, Coda Octopus Group, Inc.

(CODA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 00), +844. 4% 10Y return). SEALSQ Corp (LAES) carries a higher beta of 3. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CODA: +844. 4%, LAES: -71. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between LAES and XTLB and CODA and IDAI and INVE?

These companies operate in different sectors (LAES (Technology) and XTLB (Healthcare) and CODA (Industrials) and IDAI (Technology) and INVE (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: LAES is a small-cap quality compounder stock; XTLB is a small-cap quality compounder stock; CODA is a small-cap high-growth stock; IDAI is a small-cap quality compounder stock; INVE is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

LAES

Quality Business

  • Sector: Technology
  • Market Cap > $100B
  • Gross Margin > 22%
Run This Screen
Stocks Like

XTLB

Quality Business

  • Sector: Healthcare
  • Market Cap > $20B
  • Gross Margin > 15%
Run This Screen
Stocks Like

CODA

High-Growth Compounder

  • Sector: Industrials
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 8%
Run This Screen
Stocks Like

IDAI

High-Growth Disruptor

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 35%
  • Gross Margin > 35%
Run This Screen
Stocks Like

INVE

Quality Business

  • Sector: Technology
  • Market Cap > $100B
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.